At the 2013 MDF conference, Dr. Tom Cooper of Baylor College of Medicine presented a summary of the ninth meeting of the International Myotonic Dystrophy Consortium (IDMC).
Researchers have published several recent studies on advances in DM research.
Ionis Pharmaceuticals (formerly Isis Pharmaceuticals, Inc.) announced the identification of a drug development candidate, IONIS-DMPKRx, designed to treat Myotonic Dystrophy Type 1 (DM1), which they plan to advance into human clinical trials next year.
Timeline of key discoveries in myotonic dystrophy research since DM was first described in 1909.
Nicholas Johnson, MD, and researchers at the University of Rochester recently published an article in The Journal of Child Neurology that describes the impact of childhood and congenital myotonic dystrophy on quality of life.